TITLE

Radiation oncology

PUB. DATE
August 1997
SOURCE
Clinical & Investigative Medicine;Aug97 Supplement, Vol. 20, pS84
SOURCE TYPE
Academic Journal
DOC. TYPE
Abstract
ABSTRACT
Presents an abstract of the research manuscript `Controlled clinical trial in high metastatic risk carcinoma of the prostate comparing pelvic radiotherapy alone to pelvic radiotherapy plus LHRH analogue,' by M. Bolla et al.
ACCESSION #
9708176026

 

Related Articles

  • RADIATION THERAPY FOR UROLOGIC CANCERS. Trabulsi, Edouard J.; Zeltser, Ilia S.; Valicenti, Richard K. // Contemporary Urology;Nov2007, Vol. 19 Issue 11, p20 

    The article discusses the developments in the treatment of prostate cancer, urothelial carcinoma of the bladder and seminoma using radiation therapy (RT) as of November 2007. Various forms of RT are available for treating localized, locally advanced and metastatic prostate cancer as well as aid...

  • Goserelin Implant.  // AHFS Consumer Medication Information;Jan2017, p1 

    Goserelin implant is used in combination with radiation therapy and other medications to treat localized prostate cancer and is used alone to treat the symptoms associated with advanced prostate cancer. It is also used to treat advanced breast cancer in certain women. It is also used to manage...

  • LHRH investigation still active, despite settlement. Kerr, Richard R. // Urology Times;Feb2002, Vol. 30 Issue 2, p1 

    Focuses on the federal investigation on the marketing and selling of LHRH agonists for prostate cancer in California. Initiation of the investigation by the Office of Inspector General of the U.S. Department of Health and Human Services; Confirmation of the gathered information; Composition of...

  • Failure of long term luteinising hormone releasing hormone treatment for prostatic cancer to suppress serum luteinising hormone and testosterone. Keble, D.; Williams, Gordon; Ware, H.; Bloom, S.R. // British Medical Journal (Clinical Research Edition);8/25/1984, Vol. 289 Issue 6443, p468 

    Examines the long term luteinizing hormone releasing hormone treatment for prostatic cancer in Great Britain. Failure of treatment; Implication in serum lutenizing hormone and testosterone; Improvement in daily administration.

  • New GnRH-blocker for advanced prostate cancer.  // British Journal of Hospital Medicine (17508460);Apr2009, Vol. 70 Issue 4, p189 

    The article reports on the launch of the Degarelix, a new gonadotrophin-releasing hormone receptor blocker for the treatment of patients with advanced hormone-dependent prostate cancer.

  • Dual Interim Report of Low-dose Estramustine Phosphate (EMP) Monotherapy and Very Low-dose EMP Therapy Combined with LH-RH Agonist for Previously Untreated Advanced Prostate Cancer. Kitamura, Tadaichi; Nishimatsu, Hiroaki; Suzuki, Motofumi; Mohammed, Rafiq; Tomita, Kyouichi; Takahashi, Satoru; Takeuchi, Takumi; Ohota, Nobutaka; Kameyama, Shuji // Journal of Applied Research;2005, Vol. 5 Issue 2, p331 

    Purpose: To assess the efficacy and toxicity of oral estramustine phosphate (EMP) administration, low-dose EMP monotherapy (Study 1) and very low-dose EMP therapy combined with Iuteinizing hormone-releasing hormone (LH-RH) agonist (Study 2) were conducted in previously untreated advanced...

  • Efficacy of Combination Therapy for Prostate Cancer. Walling, Anne D. // American Family Physician;11/15/2002, Vol. 66 Issue 10, p1962 

    Provides information on a trial of an analog of luteinizing hormone-releasing hormone as adjunctive therapy to external radiation in prostate cancer. Number of men who were randomly assigned to therapy; Sites of disease progression.

  • Current Drug Therapy for Prostate Cancer: An Overview. Stewart, Alistair B.; Lwaleed, Bashir A.; Douglas, David A.; Birch, Brian R. // Current Medicinal Chemistry - Anti-Cancer Agents;Nov2005, Vol. 5 Issue 6, p603 

    Prostate cancer is the most common cancer amongst men in the USA and the second most common malignant cause of male death worldwide after lung cancer. The life time risk of having microscopic evidence of prostate cancer for a 50 year old man is 42%. Prostate cancer is thus becoming an...

  • AHCPR: LHRH agonists are equally effective.  // Urology Times;Mar99, Vol. 27 Issue 3, p3 

    Cites an Agency for Health Policy Research report which said that luteinizing hormone-releasing agonists produce roughly the same survival and side effects in men with advanced prostate cancer, regardless of which of the testosterone-suppressing drugs is taken.

Share

Read the Article

Courtesy of VIRGINIA BEACH PUBLIC LIBRARY AND SYSTEM

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics